Positron emission tomography scanning in the setting of post-transplant lymphoproliferative disorders

Clinical Transplantation

Volumn 23, Issue 6, 2009, Pages 794-799

  Blaes, Anne H ^a   Cioc, Adina M ^b   Froelich, Jerry W ^a   Peterson, Bruce A ^a   Dunitz, Jordan M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Bone marrow transplantation; Lymphoma; Organ transplantation; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE MARROW METASTASIS; BRAIN LYMPHOMA; CANCER RELAPSE; CEREBROVASCULAR DISEASE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT CANCER; STAGING; STOMACH INJURY; TREATMENT RESPONSE; ADOLESCENT; BIOPSY; COMPARATIVE STUDY; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; FLOW CYTOMETRY; FOLLOW UP; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHOPROLIFERATIVE DISORDERS; MEDIASTINUM; MIDDLE AGED; ORGAN TRANSPLANTATION; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCINTISCANNING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOPSY; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHOPROLIFERATIVE DISORDERS; MALE; MEDIASTINUM; MIDDLE AGED; ORGAN TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 71149083901     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00938.x     Document Type: Article

References (31)

1. Swinnen L, Mullen G, Carr TJ. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995, 86:3333.
2. Boubenider S, Hiesse C, Goupy C. Incidence and consequences of PTLD. J Nephrol 1997, 10:136.
3. Swinnen LJ. Diagnosis and treatment of transplant related lymphoma. Ann Oncol 2000, 11(Suppl. 1):45.
4. Morrison V, Dunn D, Manivel C. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994, 97:14.
5. Ghobrial I, Habermann T, Maurer M. Proposed prognostic model for survival in solid organ transplant receipients with posttransplant lymphoproliferative disorders (PTLD) [abstract]. Blood 2003, 102:392a.
6. Blaes A, Peterson B, Bartlett N. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation. Cancer 2005, 104:1661.
7. Juweid M, Cheson B. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006, 354:496.
8. Elstrom R, Guan L, Baker G. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003, 101:3875.
9. Juweid M, Stroobants S, Hoekstra O. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007, 25:571.
10. Schoder H, Noy A, Gonen M. Intensity of 18-flourodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkins lymphoma. J Clin Oncol 2005, 23:4643.
11. Kostakoglu L, Coleman M, Leonard JP. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002, 43:1018.
12. Spaepen K, Stroobants S, Dupont P. Early restaging positron emission toography with (18)F-flourodeoxyglucose predicts outcome in patients with aggressive non-Hodgkins lymphoma. Ann Oncol 2002, 13:1356.
13. Moormeier JA, Williams SF, Golomb HM. The staging of non-Hodgkins lymphoma. Semin Oncol 1990, 17:43.
14. Dummer JS, Bound LM, Singh G. Epstein-Barr virus induced lymphoma in a cardiac transplant patient. Am J Med 1984, 77:179.
15. Starzl TE. Discussion of Murray JE, Wilson RE, Tilney NL, et al. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968, 168:416.
16. Penn I, Hammond W, Brettschneider L. Malignant lymphomas in transplantation patients. Transplant Proc 1969, 1:106.
17. Becherer A, Mitterbauer M, Jaeger U. Positron emission tomography with [18F]2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose chemotherapy with stem cell transplantation. Leukemia 2002, 16:260.
18. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988, 6:931.
19. Cheson BD, Pfistner B, Juweid ME. Recommendations for revised response criteria for malignant lymphomas. J Clin Oncol 2006, 24:423s. (Supplement; abstract 7507)
20. Gambhir SS, Czernin J, Schwimmer J. A tabulated summary of the FDG PET literature. J Nucl Med 2001, 42(Suppl.):1S.
21. Juweid M, Cheson B. Role of positron emission tomography in lymphoma. J Clin Oncol 2005, 23:4577.
22. Allen-Auerbach M, Quon A, Weber WA. Comparison between 2-deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004, 6:411.
23. Pan MH, Chang YL, Wu YW. Gallium-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in postransplant lymphoproliferative disorder. Clin Nucl Med 2004, 29:329.
24. Tamai K, Koyama T, Saga T. Posttransplant lymphoproliferative disorder in a lung transplant recipient. J Thorac Imaging 2005, 20:280.
25. Marom E, McAdams HP, Butnor K. Positron emission tomography with fluoro-2-deoxy-d-glucose (FDG-PET) in the staging of posttransplant lymphomproliferative disorder in lung transplant recipients. J Thorac Imaging 2004, 19:74.
26. O'Conner AR, Franc BL. FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation. Nucl Med Commun 2005, 26:1107.
27. von Falck C, Maecker B, Schirg E. Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring. Eur J Radiol 2007, 10:1016.
28. McCormack L, Hany T, Hubner M. How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation?. Am J Transplant 2006, 6:1731.
29. Tulpule S, Mikhaeel G, Kazmiet M. B cell post transplant lymphoproliferative disorder complicating solid organ transplantation (B-PTLD): a single centre review reporting 1) results with chemo-immunotherapy (CHOP/R) and 2) the predictive ability of FDG-PET scanning to correlate with long term overall survival. Blood 2005, 106:432a. (Abstract 1500)
30. Bakker N, Pruim J, de Graaf W. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant 2006, 6:1984.
31. Bianchi E, Pascual M, Nicod M. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation 2008, 85:707.